Provenienza dei contatti di primo grado di Carsten Linnemann
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY.
11
| Subsidiary | Biotechnology | 11 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Carsten Linnemann tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Blue Earth Diagnostics Ltd.
Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom. | Medical/Nursing Services | Chairman Director/Board Member | |
Stanford University | College/University | Undergraduate Degree Undergraduate Degree | |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Chief Executive Officer Private Equity Investor | |
KITE PHARMA INC | Biotechnology | Founder Director/Board Member | |
ALLOGENE THERAPEUTICS, INC. | Biotechnology | Founder Director/Board Member | |
VV Manager LLC
VV Manager LLC Investment ManagersFinance VV Manager LLC (Vida Ventures) is a venture capital firm founded in 2017 by Arie Belldegrun, Arjun Goyal and Stefan Vitorovic. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Consultant / Advisor Private Equity Investor | |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Syncona Discovery Ltd.
Syncona Discovery Ltd. Financial ConglomeratesFinance Part of Syncona Ltd., Syncona Discovery Ltd. is a British company that provides investment services. The company is based in London, UK. Syncona Discovery was founded in 2013. | Financial Conglomerates | Director/Board Member | |
Anaveon AG
Anaveon AG BiotechnologyHealth Technology Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland. | Biotechnology | Chairman | |
Azeria Therapeutics Ltd.
Azeria Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Azeria Therapeutics Ltd. engages in the research and development of pharmaceutical products. It develops treatments for hormone resistance that targets breast and prostate cancer patients. The company was founded by Jason Carroll in 2017 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member | |
Resolution Therapeutics Ltd.
Resolution Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Resolution Therapeutics Ltd. operates as a macrophage cell therapy company. The company was founded on December 14, 2017 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
ACHILLES THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
SYNCONA LIMITED | Investment Trusts/Mutual Funds | Chief Executive Officer | |
Clade Therapeutics, Inc.
Clade Therapeutics, Inc. BiotechnologyHealth Technology Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Syncona Investment Management Ltd.
Syncona Investment Management Ltd. Investment ManagersFinance Syncona Investment Management Ltd. (Syncona) is the asset management subsidiary of Syncona Ltd. in Great Britain. Headquartered in London, the firm was co-founded by Martin Murphy alongside The Wellcome Trust. Syncona is focused on founding, building and funding a portfolio of global leaders in life science. | Investment Managers | Chairman | |
TG THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Syncona LLP
Syncona LLP Financial ConglomeratesFinance Syncona LLP operates as a healthcare investment company. It invests in companies which focus on gene therapy, cell therapy and patient stratification technologies. The company was founded on October 19, 2012 and is headquartered in London, the United Kingdom. | Financial Conglomerates | Chief Executive Officer | |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Biotechnology | Chairman | |
3I GROUP PLC | Investment Managers | Corporate Officer/Principal | |
Xention Ltd.
Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Pharmaceuticals: Major | Director/Board Member | |
Oxxon Therapeutics, Inc.
Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK. | Pharmaceuticals: Major | Director/Board Member | |
McKinsey & Co., Inc. (United Kingdom)
McKinsey & Co., Inc. (United Kingdom) Investment ManagersFinance Part of McKinsey & Co., Inc., McKinsey & Co., Inc. (United Kingdom) is a consulting firm that helps UK manufacturers embrace new technologies for digital transformation and leadership. The company is based in London, UK. Ruben Schaubroeck, McKinsey Digital's new lead for the UK, Belgium, and Netherlands offices, spoke with Thomas Farrar, a manager of communications in the firm's UK office, about the importance of speed and pace for CEOs in this new growth journey. The British company works with organizations that pursue sustainability, inclusion, and economic growth, all at the same time, to achieve strategic foresight and built-in agility in the face of the COVID-19 pandemic and the new trading relationship with the EU. | Investment Managers | Corporate Officer/Principal | |
MOMENTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Biomodal Ltd.
Biomodal Ltd. Miscellaneous Commercial ServicesCommercial Services Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Pulmagen Therapeutics LLP
Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
3i Plc
3i Plc Financial ConglomeratesFinance 3i Plc operates as an private equity firm and provides investment advice. The company was founded on July 21, 1945 and is headquartered in London, the United Kingdom. | Financial Conglomerates | Corporate Officer/Principal | |
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Miscellaneous Commercial Services | Chairman | |
University of Cambridge | College/University | Doctorate Degree | |
University of Oxford | College/University | Undergraduate Degree | |
Harvard Business School | College/University | Masters Business Admin | |
Adare Pharma Solutions, Inc.
Adare Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Adare Pharma Solutions, Inc. provides pharmaceutical outsourcing services. Its technologies are used to develop novel prescription and OTC products. Its brands include Viactiv, and Lactéol. The company was founded in 1999 and is headquartered in Lawrenceville, NJ. | Pharmaceuticals: Major | Director/Board Member | |
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Investment Banks/Brokers | Analyst-Equity | |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Director/Board Member | |
Innoskel SASU
Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | Biotechnology | Director/Board Member | |
Rice University | College/University | Undergraduate Degree | |
Human Immunology Biosciences, Inc.
Human Immunology Biosciences, Inc. BiotechnologyHealth Technology Human Immunology Biosciences, Inc. is a company based in South San Francisco, CA. Human Immunology Biosciences, Inc. was founded by Travis Murdoch, who has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Jeito Capital SASU
Jeito Capital SASU Investment ManagersFinance Jeito Capital SASU (Jeito Capital) is an Independent Venture Capital firm founded in 2018 by Rafaele Tordjman and headquartered in Paris, France. | Investment Managers | Private Equity Investor | |
New York University School of Law | College/University | Graduate Degree | |
CENTURY THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer | |
Medicines Australia
Medicines Australia Pharmaceuticals: MajorHealth Technology Medicines Australia is a non-profit organization which designs, develops, and implements health and industry policies for pharmaceutical industry. It builds and maintains relationships with government for fair reimbursement of medicines to ensure the continuation of a viable medicines industry, administers the Medicines Australia Code of Conduct which sets the standard for the ethical marketing and promotion of prescription medicines, and provides specialist advice to member companies. The organization is headquartered in Deakin, Australia. | Pharmaceuticals: Major | Director/Board Member | |
London Business School | College/University | Undergraduate Degree | |
Imperial College London | College/University | Doctorate Degree | |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Biotechnology | Director/Board Member | |
PANACEA ACQUISITION CORP. II | Financial Conglomerates | Chief Investment Officer |
Statistiche
Distribuzione geografica
Regno Unito | 27 |
Stati Uniti | 20 |
Svizzera | 3 |
Francia | 3 |
Australia | 2 |
Settori
Health Technology | 25 |
Finance | 13 |
Consumer Services | 9 |
Commercial Services | 5 |
Health Services | 2 |
Posizioni
Director/Board Member | 78 |
Chairman | 24 |
Corporate Officer/Principal | 17 |
Founder | 12 |
Independent Dir/Board Member | 10 |
Contatti più connessi
Insiders | |
---|---|
Franz Humer | 45 |
Martin Murphy | 33 |
David Tanen | 25 |
Katherine Wood | 14 |
Elisa Petris | 7 |
Caroline Stout | 6 |
Rachel Mears | 6 |
Ton Schumacher | 5 |
Rajul Jain | 5 |
Brent Pfeiffenberger | 3 |
Raul Jain | 2 |
- Borsa valori
- Insiders
- Carsten Linnemann
- Connessioni Società